NASDAQ$INGN

Inogen Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Reported record total revenue and a significant increase in domestic direct-to-consumer revenue and rental revenue compared to the same period last year.

Inogen's Q2 2021 financial results revealed a strong recovery and growth, with total revenue reaching a record $101.6 million, a 41.7% increase from Q2 2020. This growth was driven by strong consumer demand, improved average selling prices, and reduced COVID-19 impacts. The company reported net income of $5.1 million, or $0.22 per diluted share.

  • Total revenue reached a record $101.6 million, up 41.7% from Q2 2020.
  • Domestic direct-to-consumer revenue increased by 35.6% compared to the same period in 2020.
  • Rental revenue saw a significant increase of 85.2% from the same period in 2020
  • Cash, cash equivalents, and marketable securities totaled $250.0 million with no debt outstanding as of June 30, 2021.

Headline financials

Total Revenue

$102M

Previous: $71.7M+41.7%
EPS (adj)

$0.22

Previous: $0.12+83.3%
Units Sold

52.4K

No prior period
Capital Expenditures

-$3.59M

Previous: -$2.33M-54.3%
Free Cash Flow

$1.51M

Previous: $251K+500.8%
Net Income

$5.1M

Previous: $2.58M+97.8%
Operating Income

$11.7M

Previous: -$2.35M+596.4%
Gross Profit

$50.3M

Previous: $32.7M+53.7%
Cash & Equivalents

$239M

Previous: $214M+11.6%
Total Assets

$498M

Previous: $458M+8.7%
Stock-Based Comp

$3.24M

Previous: $1.28M+153.6%

Revenue & EPS history

Inogen · Revenue · Quarterly

$102M

Q2 2021+41.7%vs Q2 2020
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Forward guidance

The company expects total revenue in the second half of 2021 to be lower than the first half of 2021, with the largest negative impact on its domestic business-to-business channel. The Company also expects increased cost of goods sold per unit in the second half of 2021 due to cost inflation of materials and labor throughout the supply chain including semiconductor chips and higher freight costs and expects net losses in both the third and fourth quarters of 2021 and a net loss for full-year 2021.

Tailwinds

  • The Company plans to implement price increases across its products, which are planned to be effective as of September 1, 2021.
  • The Company will continue to make investments in clinical research.
  • The Company will continue to invest in research and development.
  • The Company will continue to build the necessary infrastructure to support future revenue growth and predictability.
  • The Company will continue to build infrastructure to support margin expansion.

Headwinds

  • Total revenue in the second half of 2021 is expected to be lower than the first half of 2021
  • Largest negative impact on its domestic business-to-business channel.
  • Increased cost of goods sold per unit in the second half of 2021 due to cost inflation of materials and labor throughout the supply chain including semiconductor chips and higher freight costs.
  • Net losses in both the third and fourth quarters of 2021
  • Net loss for full-year 2021

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-0.7%

Avg return

Earnings day

-2.0%

Avg return

5 days after

-2.0%

Avg return

30 days after

49%

26 / 53 earnings

Positive

+35.5%

Q2 2024

Best reaction

-32.2%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.4%-5.3%-11.0%
Q4 2025+4.3%+5.8%+6.0%
Q3 2025-0.6%+0.9%-1.3%
Q1 2025-11.5%-14.4%-8.1%
Q4 2024-14.8%-14.6%-28.6%
Q3 2024+15.9%+9.1%-0.7%
Q2 2024+35.5%+50.6%+43.0%
Q1 2024+14.6%+17.7%+17.7%
Q4 2023-32.2%-24.3%-13.0%
Q3 2023-1.3%-8.1%+10.0%
Q2 2023-14.6%-18.7%-20.8%
Q1 2023-6.1%-19.3%-21.9%
Q4 2022-31.4%-32.4%-46.4%
Q3 2022-12.5%-10.0%-0.8%
Q2 2022-6.9%-7.3%-6.3%
Q1 2022-2.2%-7.8%+2.0%
Q4 2021+12.6%+25.3%+13.5%
Q3 2021-6.0%-7.3%-21.6%
Q2 2021-22.8%-16.8%-22.1%
Q1 2021-3.5%-2.4%-12.8%
Q4 2020+4.6%+5.4%-4.2%
Q3 2020-7.1%+9.8%+33.0%
Q2 2020+16.4%+17.0%-6.5%
Q1 2020-21.4%-20.1%-24.2%
Q4 2019+10.2%+5.4%+26.4%
Q3 2019+17.3%+19.7%+24.4%
Q2 2019-15.4%-18.5%-20.9%
Q1 2019-28.8%-22.2%-31.8%
Q4 2018-26.4%-25.9%-35.1%
Q3 2018-18.8%-22.6%-24.8%
Q2 2018+7.7%+6.3%+21.3%
Q1 2018+21.0%+18.7%+26.7%
Q4 2017-9.3%-8.4%-7.8%
Q3 2017+16.1%+12.9%+15.0%
Q2 2017-5.6%-3.9%+0.3%
Q1 2017+0.2%-2.6%+11.9%
Q4 2016+6.8%+6.0%+11.4%
Q3 2016+13.0%+15.8%+22.3%
Q2 2016+0.9%+9.3%+8.9%
Q1 2016-6.6%
Q4 2015+20.6%
Q3 2015-1.8%
Q2 2015+13.0%
Q1 2015+4.9%
Q4 2014+1.8%
Q4 2012+1.8%
Q3 2013-1.7%
Q3 2014+6.0%
Q2 2014+3.6%
Q2 2013+3.6%
Q1 2013+12.7%
Q1 2014+12.7%
Q4 2013-1.0%
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro